The estimated Net Worth of Preston Klassen is at least $1.2 Milione dollars as of 26 January 2023. Dr Klassen owns over 380,605 units of Metacrine stock worth over $268,189 and over the last 11 years he sold MTCR stock worth over $178,422. In addition, he makes $749,375 as Pres e CEO & Director at Metacrine.
Dr has made over 5 trades of the Metacrine stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 380,605 units of MTCR stock worth $156,048 on 26 January 2023.
The largest trade he's ever made was selling 380,605 units of Metacrine stock on 26 January 2023 worth over $156,048. On average, Dr trades about 21,418 units every 67 days since 2014. As of 26 January 2023 he still owns at least 541,905 units of Metacrine stock.
You can see the complete history of Dr Klassen stock trades at the bottom of the page.
Dr. Preston S. Klassen M.D., M.H.S. is the Pres, CEO & Director at Metacrine.
As the Pres e CEO & Director of Metacrine, the total compensation of Dr S at Metacrine is $749,375. There are no executives at Metacrine getting paid more.
Dr S is 52, he's been the Pres e CEO & Director of Metacrine since . There are 1 older and 3 younger executives at Metacrine. The oldest executive at Metacrine, Inc. is Michael B. York, 56, who is the Chief Bus. Officer.
Preston's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS INC., 4224 CAMPUS POINT CT., #210, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine executives and other stock owners filed with the SEC include: